REVLIMID® (lenalidomide) is indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1–risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.

REVLIMID offers once-daily dosing for patients with del 5q MDS with or without additional cytogenetic abnormalities1

REVLIMID® 10mg, 5mg and 2.5mg Capsules Dosing Chart

  • Capsules shown are not actual size.

Continue treatment until disease progression or unacceptable toxicity.

  • Monitor complete blood counts weekly for the first 8 weeks of therapy and at least monthly thereafter. See Boxed WARNINGS

Important Dosing Information1

  • The capsules should not be opened, broken, or chewed
  • REVLIMID is primarily excreted unchanged by the kidney. Since elderly patients are more likely to have decreased renal function, care should be taken in dose selection. Monitor renal function
  • Treatment is continued or modified based on clinical and laboratory findings
  • Dose modification guidelines are recommended to manage Grade 3/4 neutropenia or thrombocytopenia. For non-hematologic Grade 3/4 toxicities judged to be related to REVLIMID, hold treatment and restart at the physician’s discretion at next lower dose level when toxicity has resolved to ≤Grade 2
  • For Grade 3 or 4 TFR, it is recommended to withhold treatment with REVLIMID until TFR resolves to ≤Grade 1
  • Patients may require dose interruption and/or reduction
  • Patients may require the use of blood product support and/or growth factors
  • Monitor CBCs weekly for the first 8 weeks, and at least monthly thereafter

  • CBC, complete blood count; CrCl, creatinine clearance; FL, follicular lymphoma; GFR, glomerular filtration rate; MDS, myelodysplastic syndromes; TFR, tumor flare reaction.

Dose adjustments are recommended in renally impaired patients with del 5q MDS.1

Explore Dose Modifications